Name | deferoxamine mesylate |
Synonyms | desferal desferalmesylate deferoxaminemesilate deferoxamine mesilate deferoxamine mesylate deferoxaminebmesylate desferalmethanesulfonate desferrioxaminebmesylate deferoxaminemethanesulfonate Deferoxamine Mesylate (300 mg) |
CAS | 138-14-7 |
EINECS | 205-314-3 |
InChI | InChI=1/C25H48N6O8.2CH4O3S/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26;2*1-5(2,3)4/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34);2*1H3,(H,2,3,4) |
Molecular Formula | C26H52N6O11S |
Molar Mass | 656.79 |
Melting Point | 148-149° |
Boling Point | 1061.9°C at 760 mmHg |
Flash Point | 596°C |
Solubility | H2O: 50mg/mL |
Vapor Presure | 0mmHg at 25°C |
Appearance | White to white-like powder |
Color | white to off-white |
Storage Condition | 2-8°C |
MDL | MFCD00058605 |
In vitro study | Deferoxamine treatment significantly increases HIF-1α binding under all culture conditions, including hypoxic and high-glucose. The mechanism of deferoxamine is through improving HIF-1α biological function through scavenging oxygen free radicals. Deferoxamine (5 μM) has significant effect on the tumor-associated stromal cells cellular multiplication, and cells die at day 7 after exposure to 50 μM and 100 μM deferoxamine. Deferoxamine (5 μM-100 μM) inhibits the proliferation of BMMSCs, and induces apoptosis of MSCs in a dose-dependent manner. Deferoxamine influences the expression of adhesion proteins on MSCs. Deferoxamine (30, 60, 120 μM) shows lower expression of HIF-1α in a concentration dependent way in AdMSCs. |
In vivo study | Deferoxamine (100 mg/kg, i.p.) lowers the mortality rate of subarachnoid hemorrhage (SAH) rat. Deferoxamine (100 mg/kg, i.p.) attenuates Evan’s blue extravasation in cortex, ameliorates the tight junction detachment and preserves the integrity of the base membrane examined in electron microscope at day 3 after SAH. Deferoxamine attenuates degradation of BBB proteins after SAH and significantly reduces ferritin expression at day 3 in the cortex, and improves neurologic behavior and cognitive deficits after experimental. Ten µL of 1 mM deferoxamine-treated wounds display significantly accelerated healing from day 7 onward and heal significantly faster than control-treated wounds in diabetic mice. Deferoxamine-treated wounds and dimethyloxalylglycine-treated wounds heal significantly faster than control-treated wounds in aged mice. In deferoxamine (10 mg/mL)-treated TG mice, there is a decrease in both soluble and insoluble Aβ40 and Aβ42. Both pGSK3β and β-catenin are significantly increased by approximately 50% in the deferoxamine-treated mice. |
Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. |
WGK Germany | 2 |
RTECS | UG5310000 |
HS Code | 29280000 |
Reference Show more | 1. Ma Donglai, Liu Aipeng, Zhang Yuanyuan, et al. Determination of Deferoxamine by Ultraviolet-Visible Spectrophotometry [J]. Analytical Laboratory, 2017, 036(003):289-291. 2. [IF = 14.593] Xin Zhang et al."Modulating degradation of sodium alginate/bioglass hydrogel for improving tissue infiltration and promoting wound healing." Bioact Mater. 2021 Nov;6:3692 3. [IF = 12.479] Junrui Wang et al."Tumor-self-targeted" thermoferroptosis-sensitization "magnetic nanodroplets for multimodal imaging-guided tumor-specific therapy." Biomaterials. 2021 Oct;277:121100 4. [IF = 8.183] Zhicheng Zhang et al."Versatile iron-vitamin K 3 derivative-based nanoscale coordination polymer augments tumor ferroptotic therapy." Nano Res. 2021 Jul;14(7):2398-2409 5. [IF = 6.313] Yijia Yang et al."Piperlongumine Inhibits Thioredoxin Reductase 1 by Targeting Selenocysteine Residues and Sensitizes Cancer Cells to Erastin." Antioxidants-Basel. 2022 Apr;11(4):710 |
biological activity | Deferoxamine mesylate (Desferrioxamine B, DFOM) is a Deferoxamine methanesulfonate, which can form iron complexes and be used as chelating agent. Deferoxamine, an inhibitor of iron death, stabilizes HIF-1α expression and improves HIF-1α activity under hypoxia and hyperglycemia in vitro. Deferoxamine can reduce the deposition of beta-amyloid (Aβ) and induce autophagy. |
Target | Value |